Literature DB >> 9568186

Clinical contribution of bcl-2, p53 and Ki-67 proteins in pancreatic ductal adenocarcinoma.

K Mäkinen1, T Hakala, P Lipponen, E Alhava, M Eskelinen.   

Abstract

The expression of apoptosis suppressing protein bcl-2, tumour-suppressor protein p53, and proliferation marker Ki-67 and their possible prognostic value were analysed in pancreatic ductal adenocarcinoma. Fifty-two % (34/64) of the samples were positive for bcl-2 and immunostaining were mainly localized in the cytoplasm of tumour cells. Bcl-2 expression was not related to tumour grade, DNA ploidy or S-phase fraction or to any clinical parameters. In univariate analysis bcl-2 expression predicted favourable outcome (p = 0.008). Positive nuclear staining for p53 was found in 40% (24/59) of samples and 80% (60/74) of the tumours were positive for Ki-67. p53 and Ki-67 expressions were not related to patient survival. According to our results, bcl-2 expression seems to be a predictor of disease outcome and may have some clinical value in human pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9568186

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

1.  Epidermal growth factor receptor, somatostatin and bcl-2 in human pancreatic tumor xenografts. An immunohistochemical study.

Authors:  A Zalatnai
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

2.  Clinicopathological significance of Bcl-2 and Bax protein expression in human pancreatic cancer.

Authors:  Ming Dong; Jian-Ping Zhou; Hao Zhang; Ke-Jian Guo; Yu-Lin Tian; Yu-Ting Dong
Journal:  World J Gastroenterol       Date:  2005-05-14       Impact factor: 5.742

3.  Interferon gamma inhibits growth of human pancreatic carcinoma cells via caspase-1 dependent induction of apoptosis.

Authors:  K M Detjen; K Farwig; M Welzel; B Wiedenmann; S Rosewicz
Journal:  Gut       Date:  2001-08       Impact factor: 23.059

4.  Predictive value of tumor proliferative indices in periampullary cancers: Ki-67, mitotic activity index (MI) and volume corrected mitotic index (M/V) using tissue microarrays.

Authors:  Mark M Aloysius; Shivanthi J De Silva Hewavisenthi; Timothy E Bates; Brian J Rowlands; Dileep N Lobo; Abed M Zaitoun
Journal:  World J Surg       Date:  2010-09       Impact factor: 3.352

5.  Prognostic factors in resectable pancreatic cancer: p53 and bcl-2.

Authors:  R J Bold; K R Hess; A S Pearson; A M Grau; F A Sinicrope; M Jennings; D J McConkey; C D Bucana; K R Cleary; P A Hallin; P J Chiao; J L Abbruzzese; D B Evans
Journal:  J Gastrointest Surg       Date:  1999 May-Jun       Impact factor: 3.452

6.  Histopathological study of intraductal papillary mucinous tumor of the pancreas: special reference to the roles of Survivin and p53 in tumorigenesis of IPMT.

Authors:  Ma Jinfeng; Wataru Kimura; Fumiaki Sakurai; Toshiyuki Moriya; Akiko Takeshita; Ichiro Hirai
Journal:  Int J Gastrointest Cancer       Date:  2002

7.  Ki67 and P53 in Relation to Disease Progression in Metastatic Pancreatic Cancer: a Single Institution Analysis.

Authors:  Sally Temraz; Ali Shamseddine; Deborah Mukherji; Maya Charafeddine; Arafat Tfayli; Hazem Assi; Miza Salim Hammoud; Iman Makki; Samer Nassif
Journal:  Pathol Oncol Res       Date:  2018-09-05       Impact factor: 3.201

8.  Low expression of aldehyde dehydrogenase 1A1 (ALDH1A1) is a prognostic marker for poor survival in pancreatic cancer.

Authors:  Christoph Kahlert; Frank Bergmann; Janine Beck; Thilo Welsch; Carolin Mogler; Esther Herpel; Shamik Dutta; Thomas Niemietz; Moritz Koch; Jürgen Weitz
Journal:  BMC Cancer       Date:  2011-06-27       Impact factor: 4.430

Review 9.  Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer.

Authors:  R A Smith; J Tang; C Tudur-Smith; J P Neoptolemos; P Ghaneh
Journal:  Br J Cancer       Date:  2011-03-29       Impact factor: 7.640

Review 10.  Can Molecular Biomarkers Change the Paradigm of Pancreatic Cancer Prognosis?

Authors:  Javier Martinez-Useros; Jesus Garcia-Foncillas
Journal:  Biomed Res Int       Date:  2016-09-01       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.